Current perspectives between metabolic syndrome and cancer

Oncotarget. 2016 Jun 21;7(25):38959-38972. doi: 10.18632/oncotarget.8341.

Abstract

Metabolic syndrome is a cluster of risk factors that lead to cardiovascular morbidity and mortality. Recent studies linked metabolic syndrome and several types of cancer. Although metabolic syndrome may not necessarily cause cancer, it is linked to poorer cancer outcomes including increased risk of recurrence and overall mortality. This review tends to discuss the major biological and physiological alterations involved in the increase of incidence and mortality of cancer patients affected by metabolic syndrome. We focus on metabolic syndrome-associated visceral adiposity, hyperinsulinemia, hyperglycemia, insulin-like growth factor (IGF-I) pathway as well as estrogen signaling and inflammation. Several of these factors are also involved in carcinogenesis and cancer progression. A better understanding of the link between metabolic syndrome and cancer may provide new insight about oncogenesis. Moreover, prevention of metabolic syndrome - related alterations may be an important aspect in the management of cancer patients during simultaneous palliative care.

Keywords: cancer risk; hyperglycemia; inflammation; metabolic syndrome; visceral adiposity.

Publication types

  • Review

MeSH terms

  • Adiposity
  • Animals
  • Carcinogenesis
  • Disease Progression
  • Estrogens / metabolism
  • Humans
  • Hyperglycemia
  • Hyperinsulinism
  • Inflammation
  • Insulin Resistance
  • Insulin-Like Growth Factor I / metabolism
  • Metabolic Syndrome / complications*
  • Metabolic Syndrome / pathology*
  • Mice
  • Neoplasm Recurrence, Local
  • Neoplasms / complications*
  • Neoplasms / metabolism
  • Neoplasms / pathology*
  • Risk Factors
  • Signal Transduction

Substances

  • Estrogens
  • Insulin-Like Growth Factor I